#Voice of China #Interview #Commentary #SABCS 2023 #Breast Cancer

The results of a single-arm, multicenter, prospective exploratory clinical study on the neoadjuvant treatment of HR-positive, HER2-negative (HR+/HER2-) breast cancer with Dalpiciclib combined with Letrozole, led by Professor Yuanting Gu and Professor Jingruo Li from the First Affiliated Hospital of Zhengzhou University, were selected for poster presentation at the 2023 SABCS conference. The unveiling of these results has attracted widespread attention. The study shows that for patients with early or locally advanced HR+/HER2- breast cancer, the objective response rate (ORR) of Dalpiciclib combined with Letrozole is 81%. Furthermore, an evaluation of the treatment's effectiveness after 4 cycles holds potential as an optional scheme for neoadjuvant chemotherapy-free treatment. This publication has invited Professor Hong Zong from the First Affiliated Hospital of Zhengzhou University to provide a detailed introduction to this study.

Currently, the combination of docetaxel, trastuzumab, and pertuzumab is the standard first-line treatment for HER2-positive metastatic breast cancer (MBC), but still, 60% of patients experience disease progression after 2 years of treatment. The second-line treatment standards include DS-8201, T-DM1, TKIs, etc., but these options still have their limitations and do not fully meet clinical treatment needs. Therefore, the team led by Professor Jian Liu from Fujian Provincial Tumor Hospital explored a second-line treatment regimen combining pyrotinib with inetetamab(the "Chinese Dual Target") + vinorelbine. The research results were included in the 2023 SABCS conference (Abstract number: PO1-04-05). Tumor Outlook invited Professor Jian Liu to introduce this study